About Bora Pharmaceuticals
Bora Pharmaceuticals is a publicly listed company based in Taipei (Taiwan) founded in 2008. Traditional pharma company manufacturing and marketing a range of pharmaceutical products. Bora Pharmaceuticals has completed 2 acquisitions, including Pyros Pharma and Upsher-Smith. Its website bora-corp.com draws about 24 thousand monthly visits. Its focus areas include Biopharma Outsourcing, CDMO and Diversified.
Company details
Bora Pharmaceuticals was established in 2008 in Taipei, Taiwan, within the pharmaceutical sector. Research, development, manufacturing, and distribution of western medicines and health care products are handled by the company. Key offerings include Lexapro for antidepressants, Lendormin for hypnosis, Deanxit for anxiety and depression treatment, and Ebixa for Alzheimers disease management, among others. These products are primarily supplied to domestic markets in Taiwan.
- Headquarters Taipei, Taiwan
- Stage Public
- SectorsHealthcare
- Website category Finance · Investing
- Website bora-corp.com
- Social LinkedIn X
- Legal Name Bora Pharmaceuticals Co Ltd
- Annual Revenue$19.01 B9.1as on Dec 31, 2025
- Net Profit$2.98 B-22.61as on Dec 31, 2025
- EBITDA$4.23 B-7.21as on Dec 31, 2025
- Investments & AcquisitionsPyros Pharma
& 1 more
IPO & Listings of Bora Pharmaceuticals
Bora Pharmaceuticals is a publicly listed company on the TWSE with ticker symbol 6472 in Taiwan, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date15 Dec 2015
- Listed onTT: 6472
- Listed entityBora Pharmaceuticals Co Ltd
- Exchange sectorHealth technology
- ISINTW0006472004
- Share price424.50 TWD (+1.07% on the day) · 2026-10-14
- Market capitalisation53,768,030,090.00 TWD
- Price to earnings36.2
- EPS (diluted, trailing year)11.72 TWD
- Dividend yield2.38%
- Volume (last session)313,733
Financials of Bora Pharmaceuticals
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 19.01B TWD | 2.98B TWD | 4.23B TWD |
| 2024 | 17.43B TWD | 3.85B TWD | 4.56B TWD |
| 2023 | 14.20B TWD | 3.03B TWD | 5.85B TWD |
| 2022 | 10.49B TWD | 1.39B TWD | 2.25B TWD |
| 2021 | 4.90B TWD | 749.7M TWD | 1.26B TWD |
Detailed financial statements for Bora Pharmaceuticals
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Bora Pharmaceuticals
Bora Pharmaceuticals has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Pyros Pharma and Upsher-Smith.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Pyros Pharmaceuticals is a specialty pharmaceutical company focused on developing and commercializing treatments for rare diseases, with a pipeline of innovative products aimed at improving patient outcomes. | pyrospharma.com | New York, United States | 2017 | Oct 2024 | •••• | |
Manufacturer of generic drugs | upsher-smith.com | Maple Grove, United States | 1919 | Jan 2024 | $210M |
Complete acquisition details for Bora Pharmaceuticals
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Bora Pharmaceuticals
4 dated milestones of Bora Pharmaceuticals across 16 years, from founding to its latest funding, stage changes and deals.
- Founded Bora Pharmaceuticals is founded.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires Upsher-Smith.
- Acquisition Acquires Pyros Pharma.
Web traffic of Bora Pharmaceuticals
The website of Bora Pharmaceuticals (bora-corp.com) receives about 23.6K visits a month and ranks #935,458 among all websites worldwide, #8,561 in Investing.
- Monthly visits23.6K
▼ 22.4% vs previous month
- Unique visitors10.1K
per month
- Global rank#935,458
among all websites
- Category rank#8,561
Finance · Investing
- Bounce rate50%
- Pages per visit2.5
- Average visit1 min 17 sec
- DevicesDesktop 14% · Mobile 86%
Websites whose visitors overlap most with Bora Pharmaceuticals. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
genetinfo.com | genetinfo.com | 100% | #1,121,777 | – | |
moneyweekly.com.tw | moneyweekly.com.tw | 89% | #214,273 | – | |
| moneydj.com | 86% | 8.4M | #9,834 | View details | |
uanalyze.com.tw | uanalyze.com.tw | 86% | #94,922 | – | |
| simplywall.st | 86% | 5.3M | #12,875 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 7 similar websites and full traffic analytics for Bora Pharmaceuticals
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 7 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Bora Pharmaceuticals
Complete news archive for Bora Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Bora Pharmaceuticals
Bora Pharmaceuticals was founded in 2008.
Bora Pharmaceuticals is headquartered in Taipei, Taiwan.
Bora Pharmaceuticals was established in 2008 in Taipei, Taiwan, within the pharmaceutical sector. Research, development, manufacturing, and distribution of western medicines and health care products are handled by the company. Key offerings include Lexapro for antidepressants, Lendormin for hypnosis, Deanxit for anxiety and depression treatment, and Ebixa for Alzheimers disease management, among others. These products are primarily supplied to domestic markets in Taiwan.
Yes, Bora Pharmaceuticals is publicly traded on TWSE under the ticker symbol 6472.
Bora Pharmaceuticals has made 2 acquisitions, including Pyros Pharma, and Upsher-Smith.